TD Cowen initiated coverage of Upstream Bio (UPB) with a Buy rating. The firm says the company’s verekitug is a “differentiated fast follower” with greater potency and extended dosing intervals versus Tezspire. Tge Phase 1 data have shown “rapid, deep, and sustained effects” on asthma biomarkers, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UPB: